Anakinra Response Prediction via Gene Expression Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatoid arthritis (RA) with anakinra have variable effectiveness due to limited bioavailability and lack of predictive markers for patient responsiveness, making it challenging to identify which patients will benefit from the therapy.
Innovation Solution
A method involving the measurement of specific gene expression levels in biological samples, including GTF2F2, CCT3, CROT, HNRPA3, ARL15, TMED5, and NRG3, to predict patient responsiveness to anakinra treatment, which can be used to classify patients as responders or non-responders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anakinra treatment is administered to RA patients, then disease symptoms are improved and quality of life is enhanced, but treatment effectiveness varies significantly across different patients due to limited bioavailability
Solution Approach 1:
The patent applies preliminary action by measuring gene expression levels (specifically IL-1β and IL-1Ra ratios) before initiating anakinra treatment to predict which patients will respond favorably. This pre-screening approach allows clinicians to identify responsive patients in advance, avoiding ineffective treatments and ensuring that only likely responders receive the therapy, thereby resolving the variability in treatment effectiveness across different patients
2Measurement precision
If gene expression measurement methods are developed to predict treatment response, then patient responsiveness can be accurately identified, but no reliable predictive markers have been identified to date
Solution Approach 1:
The patent applies feedback by measuring the ratio of IL-1β to IL-1Ra gene expression levels in patients before treatment and using this information to predict treatment response. This feedback mechanism provides clinicians with actionable data about which patients are likely to respond to anakinra, thereby establishing reliable predictive markers where none previously existed and enabling precision medicine approaches in rheumatoid arthritis treatment
Data Source
AI summary
The invention relates to a method for predicting the response of a patient to a treatment with anakinra, said method comprising a step of measuring the expression level of 7 genes in a biological sample of said patient, wherein said genes are GTF2F2, CCT3, CROT, HNRPA3, ARL15, TMED5, and NRG3.